Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc. (ORMP) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
ormp · stock forecast · 8 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 8 Wall Street analysts in the past 3 months
Buy
8 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $3.64
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $3.46 | ↓ 5.00% |
1-day model range: $3.43–$3.48. Peak: $3.48 (-5.00%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $3 | -29.3% |
| 2028 | $2 | -39.6% |
| 2029 | $2 | -44.1% |
| 2030 | $2 | -46.1% |
| 2031 | — | -47.1% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · ORMP · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-05-17 | Canaccord Genuity | Maintains | Hold→Hold |
| 2023-01-17 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2023-01-12 | Canaccord Genuity | Downgrade ↓ | Buy→Hold |
| 2022-05-16 | Aegis Capital | Maintains | Buy→Buy |
| 2022-02-18 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2021-11-30 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2021-11-29 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2021-11-02 | Aegis Capital | Maintains | Buy→Buy |
| 2021-07-29 | Canaccord Genuity | Maintains | Buy→Buy |
| 2021-06-08 | Aegis Capital | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Oramed Pharmaceuticals Inc. (ORMP) stock. Of the recent 19 rating actions, 0 were upgrades and 2 were downgrades. 8 analysts currently cover ORMP.
Analyst Recommendation Trends
ORMP analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$1M
↓ 66.3% YoY
Revenue Next Year
$1M
↑ 11.3% YoY
EPS This Year
$0.51
EPS Next Year
$-0.24
↓ 146.8% YoY
EPS ForecastReported vs Estimated
Analysts forecast ORMP EPS of $0.51 for the current fiscal year, based on estimates from 1 analysts. The ORMP revenue forecast is $1M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The ORMP stock forecast is supported by two independent data sources: analyst consensus ratings from 8 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ORMP price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The ORMP short-term stock prediction for tomorrow is $3.46 (-5.00%). The ORMP stock price prediction for 2027 estimates an average of $3. The ORMP stock prediction for 2030 projects a range of $2–$2.
Oramed Pharmaceuticals Inc. trades on NASDAQ under the ticker ORMP. The ORMP stock outlook for 2027 is broadly positive, supported by a Buy consensus among 75% of covering analysts.
Frequently asked questions
ORMP forecast · 8 questionsAccording to 8 Wall Street analysts, the average 12-month ORMP price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $3.64.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.